We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




MRI Monitoring Reduces Mortality in Women at High Risk of BRCA1 Breast Cancer

By MedImaging International staff writers
Posted on 05 Mar 2024
Print article
Image: MRI monitoring in women with mutations in BRCA1 genes significantly reduces breast cancer mortality (Photo courtesy of 123RF)
Image: MRI monitoring in women with mutations in BRCA1 genes significantly reduces breast cancer mortality (Photo courtesy of 123RF)

Women carrying pathogenic BRCA1 or BRCA2 gene mutations have a significantly high lifetime breast cancer risk, estimated at 70%. While about a third of these women choose to undergo risk-reducing mastectomy, the majority prefer enhanced surveillance instead. In North America, it's advised that women with BRCA1 or BRCA2 gene mutations start annual magnetic resonance imaging (MRI) screenings from age 25 or 30 up until the age of 70. It's crucial to assess how effective MRI surveillance is in reducing mortality. However, challenges such as lead time bias and the overdetection of cancer can impact survival rates. Hence, comparing mortality among women with BRCA1 or BRCA2 mutations who undergo MRI surveillance with those who do not is vital. Now, the findings of a new study suggest that MRI surveillance among women with a BRCA1 sequence variation is associated with reduced breast cancer mortality risk.

This international study that involved researchers from the Sant Pau Research Institute (Barcelona, Spain) and included data from 2.488 women from 59 centers in 11 countries highlighted a reduction in mortality associated with early detection without the need for invasive surgical interventions. The study included 2,488 women with an average age of 41.2 at entry. Of these, 1,756 (70.6%) had at least one MRI as part of their surveillance, while 732 (29.4%) underwent no MRI tests. After an average follow-up of 9.2 years, 344 women (13.8%) developed breast cancer, with 35 (1.4%) succumbing to the disease. The results, after an average of 9.2 years of follow-up, showed a significant decrease in mortality among participants.

The study underscores the importance of non-invasive monitoring methods as a preferable approach to managing breast cancer risk in women with genetic predispositions. These findings pave the way for further research on the impact of MRI surveillance in women with BRCA2 variations and may lead to reconsiderations of prevention strategies for high-risk women. The research emphasizes the value of tailoring breast cancer prevention strategies to individual needs, favoring less invasive options where feasible.

Related Links:
Sant Pau Research Institute

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Ultrasound Needle Guide
Ultra-Pro II
New
Ultrasound System
Voluson Signature 18
Computed Tomography (CT) Scanner
Aquilion Serve SP

Print article
Radcal

Channels

Nuclear Medicine

view channel
Image: The new SPECT/CT technique demonstrated impressive biomarker identification (Journal of Nuclear Medicine: doi.org/10.2967/jnumed.123.267189)

New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access

The development of lead-212 (212Pb)-PSMA–based targeted alpha therapy (TAT) is garnering significant interest in treating patients with metastatic castration-resistant prostate cancer. The imaging of 212Pb,... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.